Literature DB >> 17604290

Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation.

Felix T Range1, Michael Schäfers, Tayfun Acil, Klaus P Schäfers, Peter Kies, Matthias Paul, Sven Hermann, Betty Brisse, Günter Breithardt, Otmar Schober, Thomas Wichter.   

Abstract

AIMS: Patients with atrial fibrillation (AF) present with symptoms of myocardial ischaemia despite exclusion of coronary artery disease. A small vessel disease has been suggested. We quantified myocardial perfusion, perfusion reserve, and coronary vascular resistance (CVR) in AF patients using positron emission tomography (PET). METHODS AND
RESULTS: Twenty-five male patients (age: 58 +/- 13 years) with persistent idiopathic AF were compared with 13 age- and risk-matched male controls (age: 56 +/- 8 years). Using H(2)(15)O-PET, myocardial blood flow (MBF) was quantified at rest, at hyperaemia (adenosine), and during cold-pressor-testing (CPT). Scans were repeated 4.1 +/- 2.3 months after cardioversion in 10 AF patients. In AF, resting MBF (0.95 +/- 0.19 vs. 1.14 +/- 0.22 mL/min/mL; P = 0.009), hyperaemic MBF (2.07 +/- 0.80 vs. 3.33 +/- 0.78 mL/min/mL; P < 0.001), and MBF under CPT (0.90 +/- 0.25 vs. 1.14 +/- 0.25 mL/min/mL; P < 0.014) were significantly reduced compared with matched controls. Hyperaemic CVR was increased in AF (47 +/- 21 vs. 29 +/- 7 mmHg x mL/min/mL; P = 0.012) but unchanged at rest and under CPT. After cardioversion, resting MBF and MBF under CPT in AF were similar to matched controls, however, hyperaemic MBF and CVR were not recovered.
CONCLUSION: In AF, MBF at baseline, at hyperaemia, and at CPT is reduced, whereas CVR under hyperaemic conditions is increased. Following electrical cardioversion, these findings are partly reversible and therefore most likely secondary to the arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604290     DOI: 10.1093/eurheartj/ehm246

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  32 in total

Review 1.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 2.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

3.  Is the E/V p index useful for evaluating prognosis in chronic heart failure with atrial fibrillation? A pilot study.

Authors:  Alejandro A Diaz; Edgardo M Rodríguez; Eduardo Escudero
Journal:  J Echocardiogr       Date:  2010-03-04

4.  Microvascular dysfunction in nonfailing arrhythmogenic right ventricular cardiomyopathy.

Authors:  Matthias Paul; Kambiz Rahbar; Joachim Gerss; Peter Kies; Otmar Schober; Klaus Schäfers; Günter Breithardt; Eric Schulze-Bahr; Thomas Wichter; Michael Schäfers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-24       Impact factor: 9.236

5.  Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.

Authors:  A Bukowska; M Hammwöhner; A Sixdorf; L Schild; I Wiswedel; F-W Röhl; C Wolke; U Lendeckel; C Aderkast; S Bochmann; R K Chilukoti; J Mostertz; P Bramlage; A Goette
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 6.  Impact of Atrial Fibrillation on Coronary Blood Flow: A Systematic Review.

Authors:  George E Kochiadakis; Eleftherios M Kallergis
Journal:  J Atr Fibrillation       Date:  2012-10-06

7.  Myocardial perfusion in patients with non-ischaemic systolic heart failure and type 2 diabetes: a cross-sectional study using Rubidium-82 PET/CT.

Authors:  Christina Byrne; Philip Hasbak; Andreas Kjaer; Jens Jakob Thune; Lars Køber
Journal:  Int J Cardiovasc Imaging       Date:  2017-12-28       Impact factor: 2.357

8.  Atrial fibrillation in heart failure: The sword of Damocles revisited.

Authors:  Muhammad A Khan; Fozia Ahmed; Ludwig Neyses; Mamas A Mamas
Journal:  World J Cardiol       Date:  2013-07-26

Review 9.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

Review 10.  Symptoms In Atrial Fibrillation: A Contemporary Review And Future Directions.

Authors:  Steven T Heidt; Anna Kratz; Kayvan Najarian; Afton L Hassett; Hakan Oral; Richard Gonzalez; Brahmajee K Nallamothu; Daniel Clauw; Hamid Ghanbari
Journal:  J Atr Fibrillation       Date:  2016-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.